Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$71.98
+$0.05 · +0.07%
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Latest quote
$71.98
+$0.05 · +0.07%
After-hours
$71.98
$0.00 · 0.00%
Oct 8, 4:43 PM ET
Regular session · ET · Market data may be delayed.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Day range
Current $71.98
52-week range
Current $71.98
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
95
Deep Value
Sentiment
49
Mixed
Risk
29
Moderate Risk
Momentum
46
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Day range
Current $71.98
52-week range
Current $71.98
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 883.37M USD | 614.38M USD | 486.82M USD | 316.39M USD | 216.14M USD |
| Cost of goods sold | 432.73M USD | 250.21M USD | 181.51M USD | 138.79M USD | 100.61M USD |
| Gross profit | 450.64M USD | 364.17M USD | 305.3M USD | 177.6M USD | 115.53M USD |
| Research and development | 51.66M USD | 44.58M USD | 34.29M USD | 22.32M USD | 11.37M USD |
| Selling, general, and administrative | 317.75M USD | 249.64M USD | 161.7M USD | 124.04M USD | 84.29M USD |
| Operating expenses | 369.41M USD | 363.58M USD | 258.33M USD | 212.88M USD | 155.32M USD |
| Interest expense | 20.06M USD | 17.6M USD | 26.94M USD | 28.05M USD | 11.92M USD |
| Depreciation and amortization | 91.42M USD | 67.73M USD | 59.79M USD | 59.65M USD | 47.25M USD |
| Operating income | 81.23M USD | 584K USD | 46.97M USD | −35.28M USD | −39.79M USD |
| Net income | 78.34M USD | −18.52M USD | 18.78M USD | −47.9M USD | −42.6M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$99.50
38.23% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 18, 2013 | 1:6 | — | — |
Stock split | Jun 4, 2012 | 1:6 | — | — |
Stock split | Jun 3, 2002 | 1:10 | — | — |
Effective Jul 18, 2013
1:6
Effective Jun 4, 2012
1:6
Effective Jun 3, 2002
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR86.61M0.08%104.29B USD0.06%$137.31+0.17%
Avantis U.S. Small Cap Value ETFAVUV53.74M0.18%30.54B USD0.25%$120.13+0.84%
Vanguard Morningstar Total Stock Market ETFVTI45.02M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM38.65M0.05%78.56B USD0.19%$277.57-0.05%
Invesco Pharmaceuticals ETFPJP16.81M3.09%542.27M USD0.58%$120.96-0.47%
Vanguard Extended Market ETFVXF15.47M0.02%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO13.76M0.10%14.25B USD0.24%$353.47-0.53%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM13.48M0.08%16.01B USD0.03%$53.36+0.15%iShares Core S&P Small-Cap ETFIJRAvantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMInvesco Pharmaceuticals ETFPJPVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
